CLINICAL TRIALS PROFILE FOR COPAXONE

All Clinical Trials for copaxone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00039988 ↗	Treatment of Multiple Sclerosis With Copaxone and Albuterol	Completed	Autoimmunity Centers of Excellence	N/A	2001-11-01	The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
NCT00039988 ↗	Treatment of Multiple Sclerosis With Copaxone and Albuterol	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	2001-11-01	The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS). MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
NCT00078338 ↗	Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis	Completed	Pfizer	Phase 4	2004-02-16	The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
NCT00078338 ↗	Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis	Completed	EMD Serono	Phase 4	2004-02-16	The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
NCT00099502 ↗	BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients	Completed	Bayer	Phase 3	2003-11-01	The purpose of this study is to determine - whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms - whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg
NCT00101959 ↗	Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects	Withdrawn	EMD Serono	Phase 4	2004-11-01	Brief Summary: 800 RRMS Subjects currently treated with Avonex or Copaxone will be randomized to either continue on their current therapy or receive Rebif therapy. The subjects will be followed for 2 years. The primary objective is to compare the time to worsening to a medium level of concern as defined by the Canadian Multiple Sclerosis Working Group (CMSWG) treatment optimization recommendations.
NCT00176592 ↗	Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI	Unknown status	Stuart D Cook MD	Phase 4	2003-01-01	This is the first comparison of efficacy of Betaseron and Copaxone for treatment of relapsing forms of MS.

Clinical Trial Conditions for copaxone

Condition Name

Condition Name for copaxone
Intervention	Trials
Multiple Sclerosis	17
Relapsing Remitting Multiple Sclerosis	10
Relapsing-Remitting Multiple Sclerosis	7
Multiple Sclerosis, Relapsing-Remitting	4

Condition MeSH

Condition MeSH for copaxone
Intervention	Trials
Multiple Sclerosis	42
Sclerosis	42
Multiple Sclerosis, Relapsing-Remitting	31
Macular Degeneration	2

Clinical Trial Locations for copaxone

Trials by Country

Trials by Country for copaxone
Location	Trials
United States	289
Germany	31
Canada	23
Brazil	21
Italy	16

Trials by US State

Trials by US State for copaxone
Location	Trials
California	17
New York	15
Ohio	13
Illinois	11
Washington	11

Clinical Trial Progress for copaxone

Clinical Trial Phase

Clinical Trial Phase for copaxone
Clinical Trial Phase	Trials
Phase 4	15
Phase 3	13
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for copaxone
Clinical Trial Phase	Trials
Completed	30
Terminated	7
Unknown status	7

Clinical Trial Sponsors for copaxone

Sponsor Name

Sponsor Name for copaxone
Sponsor	Trials
Teva Pharmaceutical Industries	15
Teva Branded Pharmaceutical Products R&D, Inc.	12
Teva Neuroscience, Inc.	4

Sponsor Type

Sponsor Type for copaxone
Sponsor	Trials
Industry	57
Other	45
NIH	4